CAS: 173334-58-2; (2S,4S,5S,7S)-5-Amino-N-(3-Amino-2,2-Dimethyl-3-Oxopropyl)-4-Hydroxy-2-Isopropyl-7-(4-Methoxy-3-(3-Methoxypropoxy)Benzyl)-8-Methylnonanamide Hemifumarate

该化合物是一种主要用作抗血压剂的累累抑制剂,其功能是选择性地约束累累性,从而阻止将血管素转化为血管素I,这是RAAS路径中的一个关键步骤.这一机制为血压调节提供了有针对性的方法.肝素盐形式增强了化合物的溶性性和稳定性,改善了其药用动力学特征.Aliskiren hemifumate 的特征是其生物利用率高,半衰期长,允许每天服用一次.它的选择性行动将非目标效果降到最低,使其成为高血压管理的宝贵选择.该化合物通常作为口腔管理,确保患者遵守和持续治疗结果的平板.

结构式图片

欧盟法规

C&L通报

上下游产品

CAS号1236549-06-6 δN-苄氧基羰基阿利克仑 | CAS号110-17-8 富马酸,反丁烯二酸 | CAS号173338-07-3 [1S-[1R*(R*),2R... | CAS号173334-57-1 阿利吉仑 | CAS号173399-03-6 (2S,4S,5S,7S)-7... | CAS号324763-47-5 (αS,γS,δS,ζS)-N... | CAS号324763-51-1 3-氨基-2,2-二甲基丙酰胺 | CAS号503-74-2 异戊酸 | CAS号67744-70-1 3-氨基-2,2-二甲基丙腈 | CAS号7505-93-3 2-氰基-2-甲基丙酰胺 | CAS号173334-57-1 阿利吉仑

合成工艺路线路线简述

    专利信息


    专利号:US-9056816-B2
    优先权日:2011-10-25
    标 题:Process for the preparation of aliskiren
    发明人:BISWAS SUJAY; SRIMURUGAN SANKARESWARAN; KUMAR ANJUL; PANDA ATULYA KUMAR; JAMSHAD DANISH; MASAND MUKESH; BISWAS BIDYUT; BANSAL VIKAS; GUPTA ASHISH KUMAR; VIR DHARAM
    权利人:JUBILANT LIFE SCIENCES LTD
    摘要:The present invention provides a novel process and novel intermediates useful in the synthesis of pharmaceutically active compounds, especially renin inhibitors, such as Aliskiren, or a salt thereof, preferably Aliskiren hemifumarate.

    专利号:WO-2011148392-A1
    优先权日:2010-05-28
    标题 :Process for the preparation of (2s,4s,5s,7s)-n-(2-carbamyl-2- methylpropyl)-5-amino-4-hydroxy-2,7-diisopropyl-8-[4-methoxy-3-(3- methoxypropoxy)phenyl]-octanamide hemifumarate and its intermediates thereof
    发明人:SATYANARAYANA REDDY MANNE; THIRUMALAI RAJAN SRINIVASAN; ESWARAIAH SAJJA; VENKAT REDDY GHOJALA; RAMA SUBBA REDDY KARAMALA; SAHADEVA REDDY MARAMREDDY
    权利人:MSN LAB LTD; SATYANARAYANA REDDY MANNE; THIRUMALAI RAJAN SRINIVASAN; ESWARAIAH SAJJA; VENKAT REDDY GHOJALA; RAMA SUBBA REDDY KARAMALA; SAHADEVA REDDY MARAMREDDY
    摘要:The present invention relates to a process for the preparation of (2S,4S,5S,7S)-N-(2- Carbamoyl-2-methylpropyl)-5-amino-4-hydroxy-2,7-diisopropyl-8-[4-methoxy-3-(3-methoxy propoxy )phenyl]-octanamide compound of formula- 1 and its pharmaceutically acceptable salts thereof. Further, relates to the processes for the preparation of (R)-4-(2-(halomethyl)-3- methylbutyl)-l-methoxy-2-(3-methoxypropoxy) benzene and (R)-2-(4-methoxy-3-(3-methoxy propoxy) benzyl)-3-methyIbutan-l-ol useful intermediates in the synthesis of compound of formula- 1.

    专利号:WO-2012078147-A1
    优先权日:2010-12-08
    标 题:A process for the preparation of intermediates useful in the production of aliskiren
    发明人:BHANU MANJUNATH NARAYAN; NAIK SAMIR; THOMAS REJOY
    权利人:WATSON LAB INC; BHANU MANJUNATH NARAYAN; NAIK SAMIR; THOMAS REJOY
    摘要:A process for preparing 4-[(2R)-2-X-methyl)-3-methylbutyl]-1 -methoxy-2-3(3- methoxypropoxy)-benzene wherein X is a leaving group and use of this compound in the synthesis of aliskiren.

    专利号:US-9187409-B2
    优先权日:2010-10-19
    标 题 :Synthesis of Aliskiren
    发明人:SHANKAR RAMA; RAO VADALI LAKSHMANA; KUMAR PALLA VIJAY; SWAMY SAIDUGARI; RAO DASARI SRINIVASA; POTLA SRINIVASA RAO; NAGARAJU MITTAPELLY; RAVIKANTH JALDU; RAVI VIJAYA KRISHNA; MANUKONDA SESHADRI RAO; RAMESH DANDALA
    权利人:SHANKAR RAMA; RAO VADALI LAKSHMANA; KUMAR PALLA VIJAY; SWAMY SAIDUGARI; RAO DASARI SRINIVASA; POTLA SRINIVASA RAO; NAGARAJU MITTAPELLY; RAVIKANTH JALDU; RAVI VIJAYA KRISHNA; MANUKONDA SESHADRI RAO; RAMESH DANDALA; MYLAN LAB LTD
    摘要:The present invention provides novel process for the preparation of renin inhibitor Aliskiren or its derivatives, and its pharmaceutically acceptable salts. The present invention also provides novel intermediates used in the preparation of Aliskiren.

    专利号:EP-2313386-B1
    优先权日:2008-07-23
    标 题:Synthesis routes to 2(s),4(s),5(s),7(s)-2,7-dialkyl-4-hydroxy-5-amino-8-aryl-octanoyl amides
    发明人:VRIES DE ANDREAS HENDRIKUS MARIA; VERZIJL GERARDUS KAREL MARIA; HERMSEN PETRUS JOHANNES; CASTELIJNS ANNA MARIA CORNELIA FRANCISCA
    权利人:DSM IP ASSETS BV
    摘要:The invention relates to a process for the preparation of compounds that are important building blocks in convergent synthesis routes to 2(S),4(S),5(S),7(S)-2,7-dialkyl-4-hydroxy-5-amino-8-aryl-octanoyl amides or pharmaceutically acceptable salts thereof, such as the compound Aliskiren, and to a process for the preparation of these octanoyl amides, comprising reacting said building block.

    专利号:ES-2358536-T3
    优先权日:2005-09-28
    标题 :SYNTHESIS OF RENINAL INHIBITORS INVOLVING A CYCLOADITION REACTION.
    常州康特医药技术有限公司
    ⚠️ 未注册 · 未认证企业
    ⚠️ 该商家尚未完成注册及企业认证,请用户仔细辨别,谨慎交易。
    数据来源于公开网络搜索,平台未作核实,请自行辨别。
    🏢敬请 企业认领
    🏬开设公司展台
    📢获取免费会员权益
    🎖️点亮专属注册企业标签
    📇展现公司完整信息 样本查看立即注册认领 →
    网址: http://www.kangtepharm.com
    电话: 0519-82813797 18994752886👤
    📞常州康特医药技术有限公司 ⚠️参考联系方式

    销售电话:0519-82813797 18994752886
    邮箱:czkangte@hotmail.com
    🆔 联系时候可告知是从"百琢研"平台获取的信息.
    ⚠️ 声明: 该企业未认证、未认领,请自行辨别信息的真实性和可靠性。咨询或交易时请注意风险评估与信息核实,百琢研不参与任何交易。企业认领注册入口→

    ⚠️ 未注册 · 未认证企业
    注册入口 备注: 📌 数据来源说明:本展台内容基于各搜索引擎等公开数据整理,仅作展示用途。请用户自行辨别 ✉️ 若企业需抹除展台内容或有异议, 请通过页面底部联系方式告知我们,我们会尽快处理。
    杭州鼎燕化工有限公司
    ⚠️ 未注册 · 未认证企业
    ⚠️ 该商家尚未完成注册及企业认证,请用户仔细辨别,谨慎交易。
    数据来源于公开网络搜索,平台未作核实,请自行辨别。
    🏢敬请 企业认领
    🏬开设公司展台
    📢获取免费会员权益
    🎖️点亮专属注册企业标签
    📇展现公司完整信息 样本查看立即注册认领 →
    网址: http://www.dingyanchem.com
    企业联系电话:18267553885👤
    📞杭州鼎燕化工有限公司 ⚠️参考联系方式
    联系人:林女士
    电话:18267553885
    手机:18267553885
    传真:0571-87156470
    邮箱:sales@dingyanchem.com
    通信地址: 杭州市江干区下沙19号大街571号下沙电子商务园4A601-602室
    邮编: 310018
    🆔 联系时候可告知是从"百琢研"平台获取的信息.
    ⚠️ 声明: 该企业未认证、未认领,请自行辨别信息的真实性和可靠性。咨询或交易时请注意风险评估与信息核实,百琢研不参与任何交易。企业认领注册入口→

    地址:杭州市江干区下沙19号大街571号下沙电子商务园4A601-602室
    ⚠️ 未注册 · 未认证企业
    注册入口 备注: 📌 数据来源说明:本展台内容基于各搜索引擎等公开数据整理,仅作展示用途。请用户自行辨别
    ✉️ 若企业需抹除展台内容或有异议, 请通过页面底部联系方式告知我们,我们会尽快处理。
    第 1 / 1 页
    现货

    供应商参考报价(招募中)

    品牌试剂参考报价(招募中)

    📌 第三方产品分析报告

    ✅ COA系统入驻 | 共享模式

    主要参考文献


    1: Kappert K, Unger T, Kintscher U. Aliskiren [Aliskiren hemifumarate]. Dtsch Med Wochenschr. 2008 Jun;133(24):1308-12. German. doi: 10.1055/s-2008-1077232. Epub 2008 May 9. 27(15):4828. doi: 10.3390/molecules27154828.
    3: Ali AK. Pharmacovigilance analysis of adverse event reports for aliskiren hemifumarate, a first-in-class direct renin inhibitor. Ther Clin Risk Manag. 2011;7:337-44. doi: 10.2147/TCRM.S23889. Epub 2011 Aug 9.
    4: Salim MM, Ebeid WM, El-Enany N, Belal F, Walash M, Patonay G. Simultaneous determination of aliskiren hemifumarate, amlodipine besylate, and hydrochlorothiazide in their triple mixture dosage form by capillary zone electrophoresis. J Sep Sci. 2014 May;37(9-10):1206-13. doi: 10.1002/jssc.201301140. Epub 2014 Mar 25. 53(7):1178-84. doi: 10.1093/chromsci/bmu213. Epub 2015 Jan 9. 47(3):425-6, 428-30. doi: 10.1331/JAPhA.2007.07504. 24(15):2807. doi: 10.3390/molecules24152807.

    合成参考文献


    参考文献:10.1021/ml200137x
    摘要:Jia L, Simpson RD, Yuan J, Xu Z, Zhao W, Cacatian S, Tice CM, Guo J, Ishchenko A, Singh SB, Wu Z, McKeever BM, Bukhtiyarov Y, Johnson JA, Doe CP, Harrison RK, McGeehan GM, Dillard LW, Baldwin JJ, Claremon DA. Discovery of VTP-27999, an Alkyl Amine Renin Inhibitor with Potential for Clinical Utility. ACS Med Chem Lett. 2011 Oct 13;2(10):747–51.
    参考文献:10.1021/ml300168e
    摘要:Nakamura Y, Fujimoto T, Ogawa Y, Sugita C, Miyazaki S, Tamaki K, Takahashi M, Matsui Y, Nagayama T, Manabe K, Mizuno M, Masubuchi N, Chiba K, Nishi T. Discovery of DS-8108b, a Novel Orally Bioavailable Renin Inhibitor. ACS Med Chem Lett. 2012 Sep 13;3(9):754–8.
    摘要:https://pubs.acs.org/doi/abs/10.1021/acs.analchem.7b01709
    📝 需求与反馈
    尽可能描述清楚需求与问题信息
    ×

    通知